Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all...

Related Keywords

Suzhou , Jiangsu , China , Shanghai , Yulin Shi , Shaanxi , Chinese , Eli Lilly , Adimab Incyte , Innovent Biologics , National Medical Product Administration , Prnewswire Innovent Biologics Inc , Clinical Development Of Innovent , Md Anderson Cancer Center , Linkedin , Drug Evaluation , Psoriasis Area , Severity Index , Global Assessment , Dermatology Life Quality Index , Shanghai Skin Disease Hospital , Lei Qian , Vice President , Clinical Development ,